JAZZ

Jazz Pharmaceuticals plc

Tremor tracks 12 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

3 insiders sold shares within a monthSince May 28, 2026+1.5

Trials

JAZZJazz Pharmaceuticals
12Calm
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Signing up patientsPhase 250 patientsMain results: Aug 4, 2029
JAZZJazz Pharmaceuticals
12Calm
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
FinishedPhase 1/252 patientsMain results: Aug 29, 2025
JAZZJazz Pharmaceuticals
2Calm
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Signing up patientsPhase 1/260 patientsMain results: Jan 28, 2028
JAZZJazz Pharmaceuticals
2Calm
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Signing up patientsPhase 2200 patientsMain results: Dec 31, 2026
JAZZJazz Pharmaceuticals
2Calm
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
FinishedPhase 274 patientsMain results: Aug 30, 2025
JAZZJazz Pharmaceuticals
2Calm
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Signing up patientsPhase 2125 patientsMain results: Dec 29, 2027
JAZZJazz Pharmaceuticals
2Calm
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
Signing up patientsPhase 290 patientsMain results: Dec 15, 2028
JAZZJazz Pharmaceuticals
2Calm
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
Signing up patientsPhase 230 patientsMain results: Oct 25, 2028
JAZZJazz Pharmaceuticals
2Calm
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Signing up patientsPhase 3286 patientsMain results: Dec 1, 2028
JAZZJazz Pharmaceuticals
2Calm
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Running, no new patientsPhase 3920 patientsMain results: Jul 15, 2026
JAZZJazz Pharmaceuticals
2Calm
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Signing up patientsPhase 3510 patientsMain results: Jun 2028
JAZZJazz Pharmaceuticals
2Calm
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Signing up patientsPhase 3550 patientsMain results: Apr 28, 2028

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

24 sales (5 not pre-planned) · 0 purchases

Carr PatriciaSVP, Chief Accounting Officer · Nov 4, 2026Sold 1,250 sharesabout $289 thousand · not pre-planned
Carr PatriciaSVP, Chief Accounting Officer · Nov 4, 2026Sold 163 sharesabout $38 thousand · not pre-planned
GALA RENEE DPresident & CEO · Nov 3, 2026Sold 1,000 sharesabout $225 thousand · pre-planned
COZADD BRUCE CBoard member · Nov 2, 2026Sold 6,000 sharesabout $1.3 million · pre-planned
GALA RENEE DPresident & CEO · Oct 6, 2026Sold 2,000 sharesabout $473 thousand · pre-planned
COZADD BRUCE CBoard member · Oct 1, 2026

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.